摘要
目的:探讨胰激肽原酶联合血管紧张素Ⅱ受体拮抗剂(ARBs)对糖尿病肾病患者尿β2微球蛋白(β2-GM)和肾间质纤维化的影响。方法:选取2014年1月至2017年1月江苏昆山市第一人民医院收治的86例糖尿病肾病患者,随机分为研究组和对照组,每组43例。对照组在常规治疗的基础上给予ARBs治疗,研究组在对照组的基础上给予胰激肽原酶治疗。连续治疗8周后,观察两组血糖、肾功能、尿β2-GM水平及肾间质纤维化情况。结果:研究组血糖水平和肾功能明显优于对照组(P<0.01);研究组尿β2-GM水平、血清结缔组织生长因子(CTGF)和血清血管紧张素Ⅱ(AngⅡ)水平显著低于对照组(P<0.01)。结论:胰激肽原酶联合ARBs治疗糖尿病肾病,能够有效改善患者血糖水平和肾功能,同时能明显减少尿蛋白,延缓肾间质纤维化。
Objective： To investigate the effect of pancreatic kininogenase combined with angiotensin receptor blockers （ARBs）on urine β2-microglobulin （β2-GM）level and renal interstitial fibrosis in patients with diabetic nephropathy （DN）. Methods： 86 DN patients treated in our hospital from January 2015 to January 2017 were selected and randomly divided into a study group and a control group, with 43 cases in each group. Patients in the control group were treated with ARBs, while whose in the study group were treated with pancreatic kininoge- nase combined with ARBs for 8 weeks. The level of GM and renal interstitial fibrosis were compared between the two groups. Results： The blood glucose level and renal function in the study group were better than those in the control group （P〈 0. 01 ）. The urine β2-GM level, and serum connective tissue growth factor （CTGF） and an- giotensin Ⅱ （AngⅡ ）levels in the study group were significantly lower than those in the control group（P〈0.01）. Conclusion： Pancreatic kininogenase combined with ARBs could effectively improve the blood glucose level and renal function, reduce the urine protein, and delay the progress of renal fibrosis in DN patients.
出处
《广西医科大学学报》
CAS
2017年第10期1440-1443,共4页
Journal of Guangxi Medical University
关键词
胰激肽原酶
血管紧张素受体拮抗剂
糖尿病肾病
Β2微球蛋白
肾间质纤维化
pancreatic kininogenase
angiotensin receptor blockers
diabetic nephropathy
β2-microglobulin
renal interstitial fibrosis
